News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ceptaris Therapeutics, Inc. Announces Publication in JAMA Dermatology of Positive Clinical Results for Mechlorethamine Gel in Early Stage Mycosis Fungoides, the Most Common Type of Cutaneous T-Cell Lymphoma



1/30/2013 9:50:27 AM

MALVERN, Pa.--(BUSINESS WIRE)--Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that the results of a pivotal trial comparing its proprietary gel formulation of mechlorethamine hydrochloride 0.02% to pharmacy-compounded mechlorethamine ointment for the treatment of early stage mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL), have been published in JAMA Dermatology (formerly Archives of Dermatology).1

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES